BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7989924)

  • 1. Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation.
    Rohatiner A
    J Clin Oncol; 1994 Dec; 12(12):2521-3. PubMed ID: 7989924
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
    Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
    J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies.
    Micallef IN; Lillington DM; Apostolidis J; Amess JA; Neat M; Matthews J; Clark T; Foran JM; Salam A; Lister TA; Rohatiner AZ
    J Clin Oncol; 2000 Mar; 18(5):947-55. PubMed ID: 10694543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM; Le Beau MM; Anastasi J; Williams SF
    Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
    Chakraborty S; Sun CL; Francisco L; Sabado M; Li L; Chang KL; Forman S; Bhatia S; Bhatia R
    J Clin Oncol; 2009 Feb; 27(5):791-8. PubMed ID: 19124806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy-related myelodysplasia and acute myeloid leukemia.
    Bhatia S
    Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there an association between total-body irradiation and secondary acute myelogenous leukemia/myelodysplastic syndrome in patients with relapsed/refractory Hodgkin's disease treated with autologous stem-cell transplantation?
    Fung HC; Nademanee AP; Bhatia S; Forman SJ
    J Clin Oncol; 2001 Aug; 19(15):3585-8. PubMed ID: 11481369
    [No Abstract]   [Full Text] [Related]  

  • 8. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
    Gibson CJ; Lindsley RC; Tchekmedyian V; Mar BG; Shi J; Jaiswal S; Bosworth A; Francisco L; He J; Bansal A; Morgan EA; Lacasce AS; Freedman AS; Fisher DC; Jacobsen E; Armand P; Alyea EP; Koreth J; Ho V; Soiffer RJ; Antin JH; Ritz J; Nikiforow S; Forman SJ; Michor F; Neuberg D; Bhatia R; Bhatia S; Ebert BL
    J Clin Oncol; 2017 May; 35(14):1598-1605. PubMed ID: 28068180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
    Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
    Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F
    Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Stone RM; Neuberg D; Soiffer R; Takvorian T; Whelan M; Rabinowe SN; Aster JC; Leavitt P; Mauch P; Freedman AS
    J Clin Oncol; 1994 Dec; 12(12):2535-42. PubMed ID: 7989927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS
    J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndrome after autologous transplant for lymphoma.
    Anderson JR; Vose J; Kessinger A
    Blood; 1994 Dec; 84(11):3988-9. PubMed ID: 7949159
    [No Abstract]   [Full Text] [Related]  

  • 15. NMR-based metabolomic analysis of the molecular pathogenesis of therapy-related myelodysplasia/acute myeloid leukemia.
    Cano KE; Li L; Bhatia S; Bhatia R; Forman SJ; Chen Y
    J Proteome Res; 2011 Jun; 10(6):2873-81. PubMed ID: 21510650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
    Guidetti A; Carlo-Stella C; Ruella M; Miceli R; Devizzi L; Locatelli SL; Giacomini A; Testi A; Buttiglieri S; Risso A; Mariani L; Di Nicola M; Passera R; Tarella C; Gianni AM
    Cancer; 2011 Nov; 117(22):5074-84. PubMed ID: 21567384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature.
    Keung YK; Beaty MW; Pettenati M; Levitan D; Hurd DD
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):129-33. PubMed ID: 20371446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
    Friedberg JW
    Haematologica; 2008 Mar; 93(3):336-8. PubMed ID: 18310538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.